

A Conversation with the Investigators: Acute Myeloid Leukemia and Myelodysplastic Syndromes (Faculty Presentations)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following statements is **FALSE** regarding liposomal cytarabine/daunorubicin (CPX-351) for patients with acute myeloid leukemia (AML)?
  - a. It is composed of a fixed molar ratio of 5 to 1 cytarabine to daunorubicin
  - b. It is associated with an improvement in overall survival versus the 7 + 3 regimen
  - c. It is associated with a significantly worse adverse event profile versus the 7 + 3 regimen
2. The Phase III VIALE-A trial evaluating azacitidine in combination with either venetoclax or placebo for patients with treatment-naïve AML not eligible for intensive therapy demonstrated which clinical outcome on the azacitidine/venetoclax arm?
  - a. Improvement in complete remission rates only
  - b. Improvement in complete remission rates and overall survival
  - d. No significant differences between the study arms
3. Which of the following drug types best describes the mechanism of action of magrolimab?
  - a. Bcl-2 inhibitor
  - b. IDH1/2 inhibitor
  - c. FLT3 inhibitor
  - d. CD47 inhibitor
4. Based on the results of the MEDALIST trial, which of the following agents is FDA approved for patients with very low- to intermediate-risk myelodysplastic syndromes who have anemia after failure of an erythropoiesis stimulating agent and require 2 or more red blood cell units over 8 weeks?
  - a. Magrolimab
  - b. Pevonedistat
  - c. Luspatercept
  - d. Imetelstat
5. In the Phase IB/II study evaluating ivosidenib and venetoclax with or without azacitidine for patients with IDH1-mutated myeloid cancers, what was the overall response rate with the triplet therapy?
  - a. 25%
  - b. 45%
  - c. 85%
  - d. 100%